scPharmaceuticals (NASDAQ:SCPH) Price Target Cut to $12.00 by Analysts at Craig Hallum

scPharmaceuticals (NASDAQ:SCPH) had its price objective reduced by Craig Hallum from $16.00 to $12.00 in a report published on Thursday morning,Benzinga reports. Craig Hallum currently has a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a research note on Monday, August 19th.

scPharmaceuticals Stock Up 3.0 %

Shares of NASDAQ SCPH opened at $3.46 on Thursday. scPharmaceuticals has a 52-week low of $3.08 and a 52-week high of $6.71. The firm’s fifty day moving average is $4.46 and its two-hundred day moving average is $4.48. The company has a current ratio of 8.08, a quick ratio of 3.66 and a debt-to-equity ratio of 1.66.

scPharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $8.05 million during the quarter, compared to analysts’ expectations of $8.04 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. On average, analysts forecast that scPharmaceuticals will post -1.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On scPharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of SCPH. Bank of Montreal Can purchased a new position in scPharmaceuticals during the second quarter worth about $1,544,000. King Luther Capital Management Corp boosted its stake in shares of scPharmaceuticals by 51.8% in the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock valued at $9,592,000 after purchasing an additional 752,005 shares during the period. Rice Hall James & Associates LLC lifted its stake in scPharmaceuticals by 76.9% in the second quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock worth $2,163,000 after acquiring an additional 216,122 shares during the last quarter. AIGH Capital Management LLC lifted its stake in scPharmaceuticals by 3.4% in the second quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock worth $15,244,000 after acquiring an additional 115,206 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in scPharmaceuticals by 266.7% in the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after acquiring an additional 52,870 shares during the last quarter. 89.52% of the stock is currently owned by institutional investors and hedge funds.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.